X
Myasthenia Gravis approval will boost Soliris revenues
https://pharmaphorum.com/news/myasthenia-gravis-approval-will-boost-soliris-revenues/
Alexion
Alexion cuts ties with Moderna and re-focuses
Alexion cuts collaborations with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma
NHS supremo hails Alexion and Roche deals, but defends budget controls
Simon Stevens hails success in negotiating with pharma companies on price and data, and has defended NHS England’s record in promoting innovative medicines.
Alexion price cut opens up Strensiq to more patients
Managed access scheme will control costs to NHS.
Alexion appoints former Baxalta chief Hantson as CEO
Former AZ chief David Brennan expected to take over as chairman in May.
Pharma must slash rare disease drug prices – patient organisation
More rare disease drugs must also be approved, says EURORDIS.
NICE rejects second Alexion ultra-rare disease drug
NHS will not fund Kanuma for rare disease LAL-D.
Alexion lambasts NICE over rare disease ruling
Watchdog accused of ignoring stakeholder consensus and call for negotiations